Osteoporosi

Atti Vicenza 26–27 Maggio 2011
  • 43 Downloads

Riassunto

L’osteoporosi riconosce alcuni fattori di rischio quali la sedentarietà, la scarsa esposizione al sole, il fumo, la familiarità, eventuali terapie osteopenizzanti. La valutazione del rischio di frattura associato a osteoporosi si basa essenzialmente sulla valutazione densitometrica dell’osso, attraverso la mineralometria ossea computerizzata. Gli esami di laboratorio possono essere utili per il riconoscimento di forme secondarie di osteoporosi e per la valutazione del consumo osseo a scopo preventivo. Le terapie possibili sono molte e sono esaminate in dettaglio in questa rassegna.

Parole chiave

Osteoporosi Diagnosi Prevenzione Terapia 

Osteoporosis

Summary

There are many risk factors for osteoporosis, such as a sedentary lifestyle, poor sun exposure, tobacco smoking, family history and some medical treatments that cause osteopoenia. The evaluation of pathological fracture risk, related to osteoporosis, is mainly based on computerized bone densitometric analysis. Laboratory tests can be helpful in the diagnosis of osteoporosis secondary to other pathologies and in evaluating bone consumption in order to prevent further mineral loss. In this review we describe the different treatments available to prevent and reduce osteopenia.

Key words

Osteoporosis Diagnosis Prevention Therapy 

Bibliografia

  1. 1.
    Cummings SR, Black DM, Thompson DE et al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280:2077–2082PubMedCrossRefGoogle Scholar
  2. 2.
    Black DM, Cummings SR, Karpf DB et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535–1541Google Scholar
  3. 3.
    Bone HG, Hosking D, Devogelaer JP et al (2004) Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350:1189–1199PubMedCrossRefGoogle Scholar
  4. 4.
    Karpf DB, Shapiro DR, Seeman E et al (1997) Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups. JAMA 277:1159–1164PubMedCrossRefGoogle Scholar
  5. 5.
    Papapoulos SE, Quandt SA, Liberman UA et al (2005) Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women. Osteoporos Int 16:468–474PubMedCrossRefGoogle Scholar
  6. 6.
    Orwoll E, Ettinger M, Weiss S et al (2000) Alendronate for the treatment of osteoporosis in men. N Engl J Med 343:604–610PubMedCrossRefGoogle Scholar
  7. 7.
    Harris ST, Watts NB, Genant HK M et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282:1344–1352PubMedCrossRefGoogle Scholar
  8. 8.
    McClung MR, Geusens P, Miller PD et al (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333–340PubMedCrossRefGoogle Scholar
  9. 9.
    Cranney A, Wells G, Willan A et al (2002) Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 23:508–516PubMedCrossRefGoogle Scholar
  10. 10.
    Chesnut CH 3rd, Silverman S, Andriano K et al (2000) A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 109:267–276PubMedCrossRefGoogle Scholar
  11. 11.
    Miller PD, McClung MR, Macovei L et al (2005) Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 20:1315–1322PubMedCrossRefGoogle Scholar
  12. 12.
    Black DM, Delmas PD, Eastell R et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–1822PubMedCrossRefGoogle Scholar
  13. 13.
    Watts NB, Harris ST, Genant HK et al (1990) Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 323:73–79PubMedCrossRefGoogle Scholar
  14. 14.
    McCloskey E, Selby P, Davies M J et al (2004) Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study. J Bone Miner Res 19:728–736PubMedCrossRefGoogle Scholar
  15. 15.
    Hodsman AB, Steer BM (1993) Early histomorphometric changes in response to parathyroid hormone therapy in osteoporosis: evidence for de novo bone formation on quiescent cancellous surfaces. Bone 14:523–527PubMedCrossRefGoogle Scholar
  16. 16.
    Dempster DW, Cosman F, Parisien M et al (1993) Anabolic actions of parathyroid hormone on bone. Endocr Rev 14:690–709PubMedGoogle Scholar
  17. 17.
    Walsh BW, Kuller LH, Wild RA et al (1998) Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 279:1445–1451PubMedCrossRefGoogle Scholar
  18. 18.
    Cummings SR, Eckert S, Krueger KA et al (1999) The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281:2189–2197PubMedCrossRefGoogle Scholar
  19. 19.
    Ettinger B, Black DM, Mitlak BH et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282:637–645PubMedCrossRefGoogle Scholar
  20. 20.
    Cummings SR, San Martin J, McClung MR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765PubMedCrossRefGoogle Scholar
  21. 21.
    Reid IR, Ames RW, Evans MC et al (1995) Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women: a randomized controlled trial. Am J Med 98:331–335PubMedCrossRefGoogle Scholar
  22. 22.
    Lips P, Graafmans WC, Ooms ME et al (1996) Vitamin D supplementation and fracture incidence in elderly persons. A randomized, placebo-controlled clinical trial. Ann Intern Med 124:400–406PubMedGoogle Scholar
  23. 23.
    Heikinheimo RJ, Inkovaara JA, Harju EJ et al (1992) Annual injection of vitamin D and fractures of aged bones. Calcif Tissue Int 51:105–110PubMedCrossRefGoogle Scholar
  24. 24.
    Chapuy MC, Arlot ME, Duboeuf F et al (1992) Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 327:1637–1642PubMedCrossRefGoogle Scholar
  25. 25.
    Chapuy MC, Arlot ME, Delmas PD, Meunier PJ (1994) Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ 308:1081–1082PubMedGoogle Scholar
  26. 26.
    Dawson-Hughes B, Harris SS, Krall EA, Dallal GE (1997) Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 337:670–676PubMedCrossRefGoogle Scholar
  27. 27.
    Gillespie WJ, Avenell A, Henry DA et al (2000) Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database Syst Rev 2:CD000227PubMedGoogle Scholar
  28. 28.
    Tang BM, Eslick GD, Nowson C et al (2007) Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet 370:657–666PubMedCrossRefGoogle Scholar
  29. 29.
    Chesnut III CH, Skag A, Christiansen C et al (2004) Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE). Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241–1249CrossRefGoogle Scholar
  30. 30.
    Downs RW Jr, Bell NH, Ettinger MP et al (2000) Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women. J Clin Endocrinol Metab 85:1783–1788PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2011

Authors and Affiliations

  1. 1.Unità Operativa di EndocrinologiaArcispedale S. Maria NuovaReggio EmiliaItaly
  2. 2.Servizio di Endocrinologia — Arcispedale S. Maria NuovaReggio EmiliaItaly

Personalised recommendations